Angelini Announces the Launch on the Italian Market of an Innovative Active Wound Cleanser Developed by the Swiss Company APR
ROME & BALERNA, Switzerland–(BUSINESS WIRE)– The leading Italian pharmaceutical company Angelini has started the promotion and marketing of a new active wound cleanser in Italian hospitals and wound therapy centers. The innovative acid-oxidizing solution contains hypoclorous acid and is indicated for the treatment of chronic wounds. The product has been acquired based on an exclusive partnership between Angelini and the Swiss Company APR Applied Pharma Research, the owner and developer of the proprietary, patented technology TEHCLO®, which enables the production of this acidic and super-oxidizing solution. This solution creates an unfavorable environment for the growth of microorganisms and may favor the release of oxygen in the injured tissues. The new acid-oxidizing wound cleanser solution is indicated for use in the debridement, irrigation, cleansing and moistening of acute and chronic wounds like diabetic foot ulcers, pressure ulcers, lower legs ulcers and vascular ulcers.
In the field of Wound Care, Angelini is now able to provide healthcare professionals with a range of wound treatment options from active cleansing, to antisepsis and epithelialization support.
“With the launch of this product, Angelini aims at strengthening its position in the Wound Care therapeutic area fulfilling a medical need of the scientific community, which encompasses the shift from a passive method of mere cleansing to an active process supporting the physiological healing process.” states Fabio De Luca, Chief Commercial Officer Italy of Angelini Pharma Division.
“We are very proud to see this product on the Italian market“ said Paolo Galfetti, Chief Executive Officer of APR “as it represents a new and unique option to actively cleanse any kind of wound. While cleansing the wound bed, this innovative product is able to modulate the lesion’s microenvironment contributing to the control of the microbial burden, protecting from the risk of local infection, as well as sustaining physiological healing. We believe that this product, for its adaptable use along the continuum of wound care, offers the opportunity to exploit the growth forecasted in the wound cleansing market on an European basis, which is expected to hit a total value of $220 Mio in 2019. ”
The new acid-oxidizing solution has been developed based on APR’s proprietary patented technology TEHCLO®, enabling the production of an acidic and super-oxidizing solution characterized by pH<3, RedOx >1000mV and stabilized hypochlorous acid (>95% of free chlorine species).
It is intended for use in the debridement, irrigation, cleansing and moistening of acute and chronic wounds (e.g. diabetic foot ulcers, pressure ulcers, lower leg ulcers, vascular ulcers), post-surgical wounds, cuts, abrasions, burns and other lesions. As it contains hypochlorous acid as a preservative, it can prevent wound contamination by exerting a local antimicrobial effect on the wound surface. The convenient and easy-to-use spray formulation completes the product’s profile, providing healthcare professionals with a new tool for an optimized wound care.
The product is certified in EU as Class III Medical Device according to the rigorous European regulation.
About APR – APPLIED PHARMA RESEARCH
APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and licenses science driven, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR’s business model is currently focused on 2 (two) pillars: (i) internally developed and financed (alone or together with our co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stage of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries with international sales on a worldwide basis.
For press releases and other company information, please visit: www.apr.ch
About ANGELINI
Angelini is a privately-held, mid-sized international manufacturer and marketer of pharmaceutical and healthcare products in the pharmaceutical and mass-market sectors. Founded in Italy in 1919, the group has branches in 20 countries and employs 5.000 people. The pharmaceutical sector is the core business of the group, representing over 50% of the company’s over €1.4 billion 2014 revenue.
Angelini pharmaceutical products are available in over 60 countries through its branches and an extensive network of licensees and strategic agreements with local pharmaceutical companies. Over the years, the R&D department identified molecules of world importance like benzydamine and trazodone and is currently engaged in research projects in the field of pain and inflammation, CNS and infection.
At an international level, the company focuses mainly on pain relief, inflammation, CNS, cold & flu, oral care & sore throat, gynecology, disinfection. In Italy, Angelini is among the leading pharmaceutical companies in terms of volumes, one of the firms with the highest growth rate in the prescription drugs market, and a leader in self-medication sector.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160215005196/en/
Contacts
APR:
PAOLO GALFETTI (CEO)
Tel: +41 91 695 70 20
paolo.galfetti@apr.ch | www.apr.ch
or
ANGELINI:
FABIO PIERONI (Corporate Communication Director)
Tel: +39 06 78053366
f.pieroni@angelini.it | www.angelinipharma.com